ArticleJournal of periodontal research2026
Genomic Evidence on Antihypertensive Drug Targets and Oral Disease Outcomes.
Article in Journal of periodontal research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimAntihypertensive medications are widely prescribed for hypertension, yet evidence regarding their oral health safety remains limited. We aimed to investigate whether genetically proxied pharmacological actions of antihypertensive drug classes influence the risk of periodontitis and dental caries using a two-sample drug-target Mendelian randomization framework.
methodsGenetic instruments were obtained for 12 antihypertensive drug classes using variants within or near target genes associated with systolic blood pressure (SBP) in two genome-wide association study (GWAS) meta-analyses: one combining data from the International Consortium of Blood Pressure and UK Biobank, and another additionally including the Million Veteran Program (MVP) and Vanderbilt University's biorepository. Summary statistics for chronic periodontitis were obtained from the MVP GWAS, and for dental caries from the Gene-Lifestyle Interactions in Dental Endpoints consortium using the decayed, missing, and filled surfaces index. Causal effects were estimated using the inverse-variance weighted method with Benjamini-Hochberg correction for multiple testing. Colocalization analyses assessed whether drug targets and outcomes shared causal variants.
resultsGenetically proxied diazoxide acting through the KCNJ11 locus was associated with chronic periodontitis after multiple-testing correction (odds ratio [OR] per 1 mmHg lower SBP: 1.06, 95% confidence interval [CI]: 1.02-1.09), with consistent estimates after excluding variants associated with type 2 diabetes. No other associations were observed. Colocalization analyses provided no evidence of shared causal variants.
conclusionWe found little evidence that genetically proxied on-target pharmacological actions of antihypertensive drug classes were associated with periodontitis or dental caries. The diazoxide-periodontitis association should be interpreted with caution, given possible residual pleiotropy at the KCNJ11 locus and the absence of colocalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.